|
| Press Releases |
|
 |
|
| Friday, April 1, 2022 |
|
|
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business |
| Eisai Co., Ltd. announced today that Eisai has acquired a majority of the shares issued by Arteryex Inc., a company that plans and develops software related to digital solutions such as provision of medical information platforms, through purchase of shares and subscription of a third-party allocation of common shares, and made it a subsidiary, as of March 31, 2022. more info >> |
|
|
エーザイ、デジタルソリューションビジネスの基盤強化と迅速な拡大をめざしたArteryexの株式取得（子会社化）に関するお知らせ |
| エーザイ株式会社は、このたび、医療情報プラットフォームの提供をはじめとしたデジタルソリューションに関するソフトウェア企画・開発会社である Arteryex 株式会社について、株式買取ならびに第三者割当増資の引受けによって過半数の株式を取得し、2022 年3 月 31 日付で子会社化したことお知らせします。 more info >> |
|
| Monday, March 28, 2022 |
|
|
Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor |
| Gilead Sciences K.K., Eisai Co., Ltd. and EA Pharma Co., Ltd. announced that Gilead acquired an approval of additional indication of Jyseleca, Janus Kinase (JAK) inhibitor, for the treatment of patients with active moderate-to-severe ulcerative colitis in Japan. more info >> |
|
|
ギリアド・エーザイ・EAファーマ、JAK阻害剤「ジセレカ(R)錠」について、既存治療で効果不十分な中等症から重症の潰瘍性大腸炎の適応追加承認を取得 |
| ギリアド・エーザイ・EAファーマ、JAK阻害剤「ジセレカ(R)錠」について、既存治療で効果不十分な中等症から重症の潰瘍性大腸炎の適応追加承認を取得 more info >> |
|
| Tuesday, March 22, 2022 |
|
|
エーザイとバイオジェン、抗アミロイドβ（Aβ）プロトフィブリル抗体レカネマブに関する最新の知見を第16回アルツハイマー・パーキンソン病学会（AD/PD(TM) 2022）において発表 |
| more info >> |
|
|
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting |
| Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on lecanemab, an investigational anti-amyloid-beta (Abeta) protofibril antibody being developed for the treatment of early Alzheimer's disease (AD), were presented at the Abeta Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) March 15-20 in Barcelona, Spain and virtually. more info >> |
|
| Wednesday, March 16, 2022 |
|
|
バイオジェンとエーザイはアルツハイマー病治療薬の提携契約を変更 |
| バイオジェン・インク（Nasdaq: BIIB、本社：米国マサチューセッツ州 ケンブリッジ、CEO：ミシェル・ヴォナッソス、以下 バイオジェン）とエーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）は、このたび、既存のアデュカヌマブ（米国の製品名ADUHELM）のコラボレーション契約を変更したことをお知らせします。 more info >> |
|
| Tuesday, March 15, 2022 |
|
|
Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen |
| Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer's disease collaboration agreement with Biogen Inc. separately announced today. more info >> |
|
|
Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments |
| Biogen Inc. and Eisai Co., Ltd. announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM (aducanumab-avwa). more info >> |
|
| Friday, March 11, 2022 |
|
|
Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting |
| Eisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
The 20th PropertyGuru Asia Property Awards Grand Final recognises Singapore's finest real estate
Jan 16, 2026 04:00: JST
|
|
|
First three HKTDC trade fairs of 2026 draw some 82,000 international buyers
Jan 15, 2026 20:46: JST
|
|
|
First three HKTDC trade fairs of 2026 draw some 82,000 international buyers
Jan 15, 2026 19:46 HKT/SGT
|
|
|
NEC Launches "NEC Composable Disaggregated Infrastructure Solution" for Distributed Computing Resources
Jan 15, 2026 17:00 JST
|
|
|
真正的賦能者——愛格法醫療於2026年歐洲放射學會議（ECR）展現影像創新風采
Jan 15, 2026 16:00 HKT/SGT
|
|
|
真正的赋能者——爱克发医疗在2026年欧洲放射学大会上展现影像创新力量
Jan 15, 2026 16:00 HKT/SGT
|
|
|
A True Empowerer - AGFA HealthCare Radiates Imaging Innovation at ECR 2026
Jan 15, 2026 16:00 HKT/SGT
|
|
|
OPPO Appoints Stagwell (STGW) Agencies in Singapore: Allison Worldwide for PR and Influencer; Assembly for Media
Jan 15, 2026 15:00: JST
|
|
|
OPPO Appoints Stagwell (STGW) Agencies in Singapore: Allison Worldwide for PR and Influencer; Assembly for Media
Jan 15, 2026 14:00 HKT/SGT
|
|
|
マツダ、「フレア」を商品改良
Jan 15, 2026 13:00: JST
|
|
|
KKR、アジアのプライベート・クレジット投資向けに25億米ドルを調達
Jan 15, 2026 10:00: JST
|
|
|
Casa Minerals Inc. Announces Non-Brokered Private Placement Raising $800,000
Jan 15, 2026 01:29 HKT/SGT
|
|
|
沙特阿拉伯公共投資基金與紅海鋁業控股有限公司簽署初步條款
Jan 14, 2026 22:06 HKT/SGT
|
|
|
沙特阿拉伯公共投资基金与红海铝业控股有限公司签署初步条款
Jan 14, 2026 22:06 HKT/SGT
|
|
|
Doubleview Confirms Metal Recoveries for Upcoming Mineral Resource Estimate and Preliminary Economic Assessment
Jan 14, 2026 21:59 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
